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Abstract

Background: Limited data are available to help identify patients with schizophrenia who are most likely to benefit from long-acting injectable
antipsychotics.
Aim: To investigate the efficacy of long-acting injectable antipsychotic paliperidone palmitate one-month formulation for preventing relapses,
factors influencing time to first relapse, and the effect of different antipsychotic adherence levels on time to first relapse in Chinese patients with
schizophrenia.
Methods: This was a post-hoc analysis from an open-label, single-arm study of stable patients (Positive and Negative Syndrome Scale total score <70;
n=367) receiving paliperidone palmitate one-month formulation at the end of an acute 13-week treatment phase, who entered a naturalistic oneyear follow-up period, either continuing with flexibly dosed paliperidone palmitate one-month formulation (75–150 mg eq.) or switching to another
antipsychotic(s).
Results: There were 362/367 patients (age=31.4±10.75 years) included in the analysis of time to first relapse (primary outcome) and 327/362
patients (39/327, poor antipsychotic adherence (<80%)) willing to receive antipsychotics were included in the exposure/adherence analysis. Overall,
84.6% (95% confidence interval=79.2–88.7) patients remained relapse-free. Poor adherence during follow-up (hazard ratio=2.97, 95% confidence
interval=1.48–5.98, p=0.002) and frequent hospitalizations in the previous year (hazard ratio=1.29, 95% confidence interval=1.02–1.62, p=0.03)
were associated with a significant risk of shorter time to first relapse in the univariate analysis. In patients with poor adherence, ‘no use’ (hazard
ratio=13.13, 95% confidence interval=1.33–129.96, p=0.03) and ‘interrupted use’ (hazard ratio=11.04, 95% confidence interval=1.03–118.60,
p=0.047) of paliperidone palmitate one-month formulation (vs continued use) showed a significantly higher risk of relapse; this was not observed in
patients with good (≥80%) antipsychotic adherence. No new safety concerns were identified.
Conclusion: Continued use of paliperidone palmitate one-month formulation/long-acting injectable antipsychotic was effective in preventing
schizophrenia relapses, especially in patients with suboptimal antipsychotic adherence.
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Introduction
Symptom exacerbations or relapses in schizophrenia during
maintenance treatment often lead to inferior outcomes and
increased hospitalization risk (Carbon and Correll, 2014; Kane,
2013; Nasrallah and Lasser, 2006). The long-term consequences

of relapses include increased risk of self-harm, decline in psychosocial and occupational abilities, increasing personal and healthcare burden, social stigmatization, and progressive clinical
deterioration (Almond et al., 2004; Kane, 2007; Thornicroft
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et al., 2009). Thus, delaying the time to relapse and achieving
optimal symptom control are fundamental objectives of schizophrenia management that are recommended by existing clinical
practice guidelines (Kane and Garcia-Ribera, 2009; Malla et al.,
2013).
Poor adherence (<70% to 80% of prescribed medications) or
nonadherence to antipsychotics is recognized as one of the
strongest risk factors for relapses in schizophrenia (Agid et al.,
2010; Ascher-Svanum et al., 2009; Kane et al., 2013; Novick
et al., 2010). Medication discontinuations substantially increase
the risk of relapse during the critical early intervention period
(first 2–5 years of illness) that determine the long-term course of
treatment outcome in schizophrenia (Birchwood et al., 1998;
Chien et al., 2016). In a survival analysis of relapses, stopping
antipsychotic medications was the strongest predictor of relapses,
increasing the risk by five-fold compared with patients continuing antipsychotic treatment (hazard ratio (HR) to first
relapse=4.89, 99% confidence interval (CI)=2.49–9.60)
(Robinson et al., 1999). Similar results were obtained in another
study of first-episode patients with schizophrenia, where nonadherence to antipsychotic treatment was the only predictor of
relapse, also increasing the relapse risk by about five-fold
(HR=4.8, 95% CI=2.9–7.7) (Caseiro et al., 2012). Medication
nonadherence was also the greatest risk factor associated with
relapse (odds ratio (OR)= 4.6, 95% CI=3.4–6.2) in a one-year
real-world study conducted in China (Xiao et al., 2015).
Additionally, results from a survey of 1854 psychiatrists from the
People’s Republic of China reported that nearly 56% (range:
30–71%) of patients with schizophrenia were either partially or
fully non-adherent to medications (Olivares et al., 2013).
The use of long-acting injectable (LAI) antipsychotics at various stages of schizophrenia (patients with first-episode, insufficient response to oral antipsychotics, or history of relapse) has
been shown to reduce nonadherence and subsequent episodes of
relapses and hospitalizations (Correll et al., 2016; Heres et al.,
2014). Extensive studies have demonstrated the therapeutic efficacy of paliperidone palmitate one-month formulation (PP1M),
an atypical LAI antipsychotic (dopamine (D2) and serotonin
(5-HT2A) receptor antagonist), along with practical advantages
of extended durations of therapeutic plasma levels, simplified
medication schedules, and efficient monitoring of treatment
schedules (Agid et al., 2010; Alphs et al., 2013; GonzalezRodriguez et al., 2015; Samtani et al., 2009). Evidence for effective relapse prevention with PP1M supporting maintenance
treatment is accrued largely from studies of non-Asian patients
(Alphs et al., 2015; Gopal et al., 2011; Hough et al., 2010;
McEvoy et al., 2014).
This post-hoc analysis was conducted in the one-year observational follow-up phase following the 13-week, acute treatment
phase of a large prospective, open-label study of flexibly dosed
PP1M in Chinese patients with acute schizophrenia showing
unsatisfactory response to prior antipsychotics (Si et al., 2015b).
The role of PP1M in the prevention of schizophrenia relapse over
a one-year period among patients who continued treatment with
PP1M or any antipsychotic (PP1M switched to other antipsychotics) was explored in the follow-up phase analyses using a
naturalistic design. Further, predictors of relapse prevention,
including the relationship between the proportion of PP1M medication usage and time to first relapse (TFR) in patients with different degrees of antipsychotic adherence, was also characterized.
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Overall, the primary objective was to evaluate the impact of
PP1M versus other antipsychotics, in preventing schizophrenia
relapse in patients with different levels of adherence and determine factors influencing TFR.

Methods
Patients and study design
Data from an open-label, single-arm, multicenter phase 4 study
(NCT01685931) were analyzed. The study was conducted
between October 2012–December 2014 at 22 sites in the People’s
Republic of China and consisted of three phases: a screening
phase of up to seven days, a 13-week acute treatment phase, and
a one-year observational follow-up phase that provided data for
the current analyses.
Details of study design and primary results have been reported
previously (Si et al., 2015b). Briefly, adults (18–65 years, inclusive) with a diagnosis of acute schizophrenia based on Diagnostic
and Statistical Manual of Mental Disorders-IV-Text Revision
(DSM-IV-TR; American Psychiatric Association, 2000) criteria
who lacked a satisfactory therapeutic effect to previous oral
antipsychotic treatment (i.e. Positive and Negative Syndrome
Scale (PANSS) total score of 70–120 at screening and baseline)
were eligible. Major exclusion criteria were: active, non-schizophrenia DSM-IV-TR axis 1 diagnosis; attempted suicide within
12 months before screening, or at imminent risk of suicidal or
violent behavior; risk factors for prolonged QT interval, torsades
de pointes, or sudden death; treatment with clozapine or monoamine oxidase inhibitor antidepressants within one month before
screening; use of LAI antipsychotics including PP1M (within six
injection intervals before screening); or use of electroconvulsive
therapy within one month before screening. For the present posthoc analysis, symptomatically stable patients (PANSS total score
<70) at week 13 who continued in the follow-up phase and
received PP1M or any antipsychotic in the first month of the
maintenance period after the 13-week acute phase were included.
An independent ethics committee at each study center
approved the study protocol. This study was conducted in accordance with the ethical principles that have their origin in the
Declaration of Helsinki and in accordance with International
Conference on Harmonization’s Good Clinical Practice guidelines and applicable regulatory requirements. All patients provided written informed consent prior to study enrollment.

Treatments
Eligible patients received (Invega Sustenna, Janssen, Division of
Ortho-McNeil-Janssen Pharmaceuticals, Inc.) deltoid injections
of PP1M at a dose of 150 mg eq. of paliperidone (PP) (equal to
234 mg of PP) on day 1 and 100 mg eq. (156 mg of PP) on day 8
followed by a monthly maintenance flexible dose between 75–
150 mg eq. (117–234 mg of PP) of PP (deltoid or gluteal injections) during the acute 13-week treatment phase. All oral
antipsychotics taken prior to study entry were gradually tapered
and then withdrawn in the first two weeks after initiation of
PP1M.
During the one-year observational follow-up phase (the focus
of this study), patients continued PP1M injection, switched to
other oral or LAI antipsychotics or continued without any
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treatment, based on patient and prescriber preference/judgment.
PP1M was provided gratis to study patients during the 13-week
acute treatment phase; patients needed to source and pay for
PP1M or other AP medications during the one-year observational
follow-up phase.

Assessments
The primary endpoint of the post-hoc analysis was estimation of
TFR during the period of analysis (30 days after a 13-week acute
treatment phase to date of the first relapse or end of study during
the follow-up phase). All patients who did not relapse during the
follow-up phase were censored at end of the study. Relapse was
defined by occurrence of one or more of the following: (a) hospitalization due to symptoms of schizophrenia (involuntary or voluntary); (b) two consecutive assessments at which PANSS total
score was increased by 25% in patients with PANSS total scores
>40 at baseline, or by 10 points in patients whose PANSS total
score was ≤40 at baseline; (c) intentional self-harm or aggressive
behavior, suicide or homicide attempts, or aggressive behavior
with clinical significance; and (d) pre-selected baseline PANSS
item scores (P1, P2, P3, P6, P7, and G8) of ≤3 increased to ≥5 in
two consecutive assessments, or item scores of four at baseline
increased to ≥6 (Hough et al., 2010).

Antipsychotic exposure and adherence. Adherence to all antipsychotics (any prescribed LAI antipsychotic and/or oral antipsychotics) was calculated as the ratio of cumulative exposure
duration of all antipsychotics (days) to TFR (days) or time to the
study completion/withdrawal (days) (for patients who did not
relapse). Details of antipsychotic use were identified by prescription. Patients treated with LAI antipsychotics were considered as
still exposed to the drug during the interval between the last
administration and the next regularly scheduled administration
(for example, if patients were only treated with PP1M, the exposure duration of PP1M was the date of the last injection+30
days). Antipsychotic exposure was treated as both a continuous
variable (percentage of time with adherence) and a categorical
variable. For the categorical variable, patients adhering to <80%
of all prescribed antipsychotics were classified as patients with
poor adherence, while those adhering to ≥80% of all prescribed
antipsychotics were considered as patients with good adherence.
Proportion of PP1M usage. The ratio of PP1M to all antipsychotics was also examined as a factor influencing TFR. Therefore, the proportion of PP1M usage was estimated to investigate
the impact of PP1M usage as compared with other antipsychotics
in preventing relapses. As the impact of PP1M was to be estimated in patients who were receiving at least some antipsychotic
therapy, patients exposed to antipsychotics for at least one day
(antipsychotic adherence >0%) were included in the analysis. As
part of the sensitivity analysis, the impact of usage of all LAI
antipsychotics (includes PP1M and other LAI antipsychotics) on
TFR was also investigated. The ratio of cumulative exposure
duration of PP1M/all LAI antipsychotics (days) to cumulative
exposure duration of all antipsychotics (days) was calculated.
Similarly to the analysis of antipsychotic adherence, patients
treated with LAI antipsychotics were considered as still exposed
to the medication during the interval between the last administration and the next regularly scheduled administration. Likewise,

the proportion of PP1M/all LAI antipsychotic usage was estimated as both a continuous variable and a categorical variable.
As a categorical variable, this parameter was divided into three
types: (a) no use PP1M/all LAI antipsychotics (proportion of
PP1M/all LAI antipsychotic usage=0), patients were not treated
by PP1M/all LAI antipsychotics before relapse or the study completion/withdrawal; (b) interrupted use PP1M/all LAI antipsychotics (proportion of PP1M/all LAI antipsychotic usage >0 but
<100%), patients received at least one injection of PP1M/all LAI
antipsychotics before relapse or the study completion/withdrawal; (c) continued use PP1M/all LAI antipsychotics (proportion of PP1M/all LAI antipsychotic usage=100%), patients
regularly received PP1M/all LAI antipsychotic treatment before
occurrence of relapse or the study completion/withdrawal.

Efficacy. The following efficacy measures were assessed during
the follow-up visits conducted every three months: PANSS total
score (range: 30–210; higher score indicates more extreme
schizophrenia psychopathology) (Marder et al., 1997), Clinical
Global Impressions-Severity (CGI-S) (scores range from 1= normal to 7=extreme) (Busner and Targum, 2007), Personal and
Social Performance (PSP) scale (71–100=not more than mild
degree of difficulty; 31–70=moderate degree of dysfunction;
≤30=functioning so poor that the patient required intensive
supervision) (Morosini et al., 2000), Medication Satisfaction
Questionnaire (MSQ; scores range from 1=extremely dissatisfied
to 7=extremely satisfied) (Gharabawi et al., 2006; Vernon et al.,
2010).

Safety. Safety evaluations included recording of treatmentemergent adverse events (TEAEs), vital signs, laboratory values
and electrocardiogram.

Statistical analysis
Since the exposure analysis was intended to assess the influence
of antipsychotic adherence and usage of PP1M on TFR, only
patients willing to take antipsychotics during the evaluation
period (adherence to all antipsychotics >0%) were included in
this post-hoc analysis. The primary endpoint (TFR) was estimated using the Kaplan-Meier method, and descriptive statistics
(number of relapses, number of censored patients, and median,
25th, and 75th percentile of time to relapse, if estimable) were
provided.
A Cox regression model was used to analyze the association
of specific variables with TFR and HR along with 95% CI.
Univariate association of individual variables with TFR was
calculated separately for patients who used PP1M or all antipsychotics during the study period. The following covariables
were entered in the univariate analysis: age, sex, monthly
income, monthly income level, number of hospitalizations in
the previous year, disease duration, adherence to all prescribed
antipsychotics (0%, >0% to <80%, >80%), proportion of PP1M
usage (no use, interrupted use versus continued use (reference
group)) and MSQ, PSP, CGI-S and total PANSS scores at baseline and endpoint during acute phase. Independent variables
with p≤0.15 in the univariate analysis and their potential interactions were examined in a stepwise screening approach to
construct the multivariate Cox regression model. A p=0.05
level of significance was applied to determine whether
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Figure 1. Patient disposition. PANSS: Positive and Negative Syndrome Scale.

variables were added or removed from the multivariate model.
The multivariate model further explored associations in two
subgroups separately (poor antipsychotic adherence versus
good antipsychotic adherence).

Results
Patient disposition and characteristics
Details of patient disposition and demographics for the acute
treatment phase are detailed in the primary study publication (Si
et al., 2015b). Of the 477 patients who completed the acute treatment phase, 367 patients who achieved PANSS<70 at week 13
were included in the analysis of relapse (Figure 1). The percentage of patients using PP1M during the one-year follow-up phase
ranged from 18.10% (57/315) to 29.01% (105/362). The number
of patients using other LAI antipsychotics was low and ranged
from 2.45% (9/367) to 3.59% (13/362). A total of 362 patients
continued the study for ≥30 days after the last PP1M injection of
the acute phase (Figure 1). The mean (standard deviation (SD))
patient age was 31.4 (10.75) years, with a slight preponderance
of men (196 (54.14%)). During the one-year follow-up period, a
majority (288 (79.59%)) of patients had good adherence (≥80%),
39 (10.77%) patients had poor adherence (<80%) while 35
(9.67%) refused any treatment. Thus, a total of 327 patients with
>0% adherence to all antipsychotics were included in the Cox
regression analysis (Table 1).

Analysis of time to first relapse
Of 367 patients who entered the one-year observational period,
362 were included in the analysis of relapse (n=5, excluded (n=1,
relapsed and n=4, discontinued within one month after 13-week
phase)). A total of 45/362 (12.4%) patients relapsed during the
one-year observational period. The estimated percentage of
patients remaining relapse-free was 84.6% (95% CI=79.2–88.7)
using the Kaplan-Meier method. The 25th percentile and median
TFR (estimated time-point at which 25% or 50% (median) of
patients experienced a relapse) could not be estimated since
<25% patients relapsed during the observational period.

Univariate analysis. In the univariate analysis, poor antipsychotic adherence (vs good) (HR=2.97, 95% CI=1.48–5.98,
p=0.002) and number of hospitalizations in the previous one year
(HR=1.29, 95% CI=1.02–1.62, p=0.03) were associated with a
significantly shorter TFR both for usage of PP1M, and all LAI
antipsychotics. Adherence to all antipsychotics, usage of PP1M
(interrupted use vs continued use), MSQ scores of patients and
caregivers at the baseline of the acute phase and total PANSS
scores at baseline in the acute phase were potentially important
contributors to TFR (p≤0.15) and thus were also included in the
multivariate Cox regression analysis (Table 2).
Multivariate analysis. In the multivariate Cox regression analysis,
proportion of PP1M exposure (%), adherence to all antipsychotics
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Table 1. Demographics and key baseline characteristics (13-week acute
treatment phase) and medication adherence distribution and summary
of long-acting injectable antipsychotic (LAI) antipsychotic usage (oneyear observational follow-up phase).
Characteristics
13-week acute treatment phase
Age, mean (SD), years
Sex, n (%)
Men
Body weight, mean (SD), kg
BMI, mean (SD), kg/m2
Duration of schizophrenia, mean (SD), years
Duration distribution of disease, n (%)
≤5 years
>5 years
PANSS total score, mean (SD)
Baseline
Week-13 acute phase
CGI-S score, mean (SD)
Baseline
Week-13 acute phase
PSP score, mean (SD)
Baseline
Week-13 acute phase
One-year observational follow-up phase
Degree of adherence to antipsychoticsa, n
(%)
0%
<80%
≥80%
LAI usageb in patients with >0% adherence,
n (%)
PP1M
No use
Interrupted use
Continued use
All LAIc
No use
Interrupted use
Continued use

Total
(n=362)
31.4 (10.75)
196 (54.14)
64.4 (12.56)
23.3 (3.76)
4.9 (5.25)
237 (65.47)
125 (34.53)
90.5 (12.04)
48.9 (10.22)
5.2 (0.73)
2.7 (0.84)
46.0 (13.53)
70.7 (8.21)

35 (9.7)
39 (10.8)
288 (79.6)
n=327

205 (62.7)
35 (10.7)
87 (26.6)
193 (59.0)
36 (11.0)
98 (30.0)

BMI: body mass index; CGI-S: Clinical Global Impressions-Severity; PANSS: Positive and Negative Syndrome Scale; PSP: Personal and Social Performance Scale;
SD: standard deviation.
aAdherence to all antipsychotics (%)=exposure duration of all antipsychotics (days)/time to the first relapse (days) or study completion/withdrawal
(days)×100. For patients on LAI antipsychotics, the last dose in the acute phase
was considered to provide continued exposure during the interval between last
dose and the next scheduled dose. For example, the actual exposure duration for
PP1M in this analysis was calculated as the date of last injection in the acute
phase+30 days. Time to the first relapse was determined as the time from the
start date to the first relapse recorded.
bThe usage of PP1M/all LAI antipsychotics was categorized according to the
percent of PP1M/all LAI antipsychotic exposure duration in all antipsychotics exposure duration during the observational follow-up phase; 0% usage was
defined as “no use;” 0–100% usage as “interrupted use;” and 100% usage as
“continued use.”
cPP1M and/or other LAI antipsychotics.

(%) and the interaction of adherence to all antipsychotics to proportion of PP1M (p=0.03) and all LAI antipsychotics (p=0.04)) exposure had a significant association with TFR (Table 3). The significant
influence of this interaction on TFR, steered the multivariate analysis to further determine any clinically important difference in the
treatment effect of PP1M and all LAI antipsychotics in delaying
TFR due to differential adherence among patients with varied LAI
antipsychotic usage patterns. Thus, the patients were categorized as
having good and poor adherence to antipsychotics, and the effect of
LAI antipsychotic usage pattern on TFR was analyzed. Other variables with a significant association with TFR included: number of
hospitalizations in the previous one year, and total PANSS score at
baseline in the acute phase. Interaction between proportion of LAI
antipsychotic usage (no use vs continuous use) and adherence to all
antipsychotics (poor vs good) were also identified as relevant contributors to TFR (PP1M: p=0.04; all LAI antipsychotics: p=0.06)
(Table 3).

Stratified analysis by good versus poor adherence. In the
largest LAI antipsychotic subgroup (all LAI antipsychotics), the
usage pattern of LAI antipsychotics did not show any significant
influence on TFR in patients with good antipsychotic adherence
(Table 4). The continued use of all LAI antipsychotics (vs no use
(log rank test: p=0.45) and interrupted use (log rank test: p=0.36)
of all LAI antipsychotics) did not have a significant effect on
relapse-free survival time in these patients and the Kaplan-Meier
plots supported this finding (Figure 2(a) and (b)). However, in
patients with poor antipsychotic adherence, the benefits of uninterrupted LAI antipsychotic usage were demonstrated from the
multivariate analysis (Table 4) as well as the Kaplan-Meier plots
(Figure 2(c) and (d)). The continued use of all LAI antipsychotics
(vs no use (log rank test: p=0.028) and interrupted use (log rank
test: p=0.014)) was associated with a significantly longer relapsefree survival period in patients with poor antipsychotic
adherence.
Regarding the use of PP1M (patients with continued or interrupted use of PP1M among all LAI antipsychotics, 122/134
(91.0%)), the findings were generally similar to those noted in
the all LAI antipsychotic subgroup. In patients with good antipsychotic adherence, no use and interrupted use of PP1M were not
associated with any significant effect on TFR, although numerically, the results indicated higher risk of relapse compared with
continued use of PP1M (continued vs no use: HR=1.18, 95%
CI=0.47–2.97, p=0.7308; continued vs interrupted PP1M use:
HR=1.59, 95% CI=0.45–5.65, p=0.4709) (Table 4). Similarly,
continued use of PP1M (vs no use (log rank test: p=0.75) and
interrupted use (log rank test: p=0.451)) did not demonstrate significant relapse-prevention benefit in patients with good antipsychotic adherence (Figure 2(e) and (f) shows the Kaplan-Meier
plot of time to relapse). Among patients with poor antipsychotic
adherence, no use (HR=13.13, 95% CI=1.33–129.96, p=0.0277)
and interrupted use (HR=11.04, 95% CI=1.03–118.60, p=0.0474)
of PP1M were associated with a significantly increased risk of
relapse vs continued use of PP1M (Table 4). A significantly
longer relapse-free survival time with continued use of PP1M (vs
no use (log rank test: p=0.035) and interrupted use (log rank test:
p=0.016)) was observed among patients with poor antipsychotic
adherence, suggesting the efficacy of PP1M maintenance therapy
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Table 2. Univariate analysis of time to first relapse.
PP1M (n=327)

Adherence to all antipsychotics (%)
Adherence distribution to all antipsychotics
(poor adherence vs good adherence)a
Usage of PP1M/all LAI antipsychotics: interrupted antipsychotic use versus continued
use
The number of hospitalizations in the previous one year (times)
MSQ scores of patients at baseline of acute
phase
MSQ scores of caregivers at baseline of
acute phase
Total PANSS scores at baseline in the acute
phase

All LAIs (n=327)

Hazard ratio

95% CI

p-Value

Hazard ratio

95% CI

p-Value

0.99
2.97

0.98–1.00
1.48–5.98

0.06
0.002

0.99
2.97

0.98–1.00
1.48–5.98

0.06
0.002

2.52

0.88–7.18

0.08

2.74

0.96–7.81

0.06

1.29

1.02–1.62

0.03

1.29

1.02–1.62

0.03

0.80

0.62–1.03

0.08

0.80

0.62–1.03

0.08

0.80

0.61–1.03

0.09

0.80

0.61–1.03

0.09

1.02

1.00–1.05

0.10

1.02

1.00–1.05

0.10

CI: confidence interval; LAI: long-acting injectable; MSQ: Medication Satisfaction Questionnaire; PANSS: Positive and Negative Syndrome Scale; PP1M: paliperidone palmitate one-month formulation; PSP: Personal and Social Performance.
aPoor adherence: adherence distribution to antipsychotics, (>0 to <80%); good adherence: adherence distribution to antipsychotics, ≥80%.
Variables tested as p≤0.15 are presented. Other variables tested: proportion of PP1M/all LAI antipsychotic exposure, usage of PP1M/all LAI antipsychotics (no use vs
continued use); sex (women vs men), age (years), monthly income (income/month; yes vs no; income levels), disease duration (years), disease duration distribution,
MSQ scores of patients at endpoint of acute phase, MSQ scores of caregivers at endpoint of acute phase, total PSP scores at baseline and endpoint of acute phase, CGI-S
scores at baseline and endpoint of acute phase, total PANSS scores at baseline and endpoint of acute phase.

Table 3. Multivariate Cox regression analysis of first time to relapse (day) to investigate interaction between adherence to all antipsychotic
medications and proportion of paliperidone palmitate one-month formulation (PP1M)/all long-acting injectable (LAI) antipsychotic usage.
PP1M (n=327)
Estimate
Model 1: variables of interest included in continuous format
Proportion of PP1M or all LAI antipsychotics exposure (%) −0.04
Adherence to all antipsychotics (%)
−0.02
Proportion of PP1M or all LAI andtipsychotics exposure (%) 0.0004
× adherence to all antipsychotics (%)
Total PANSS scores at baseline in the acute phase
0.03
The number of hospitalizations in the previous one year
0.34
(times)
Model 2: variables of interest included in classified format
Usage of PP1M or all LAI antipsychotics
No use versus continued use
−0.04
Interrupted use versus continued use
0.34
Adherence distribution of all antipsychotics (poor adher−0.65
ence vs good adherence)a
Interaction between adherence to all antipsychotics and
usage of PP1M or all LAI antipsychotics
Usage of PP1M or all LAI antipsychotics (no use vs con- 2.47
tinued use) × adherence distribution to all antipsychotics (>0−80% vs ≥80%)
Usage of PP1M or all LAI antipsychotics (interrupted
1.87
use vs continued use) × adherence distribution to all
antipsychotics (>0−80% vs ≥80%)
The number of hospitalizations in the previous one year
0.25
(times)
Total PANSS scores at baseline in the acute phase
0.03

SE

All LAIs (n=327)
Chi-square p-Value

Estimate SE

Chi-square

p-Value

0.01
0.01
0.0002

5.18
9.85
4.08

0.02
0.002
0.04

0.02
5.44
0.01
10.31
0.0002 4.73

0.02
0.001
0.03

−0.03
−0.02
0.0003

0.01
0.14

4.38
5.80

0.04
0.02

0.03
0.33

0.01
0.14

4.38
5.47

0.04
0.02

0.53
0.74
1.14

0.00
0.21
0.33

0.94
0.65
0.57

0.14
0.44
−0.51

0.53
0.74
1.14

0.07
0.35
0.21

0.79
0.55
0.65

1.23

4.08

0.04

2.31

1.22

3.59

0.06

1.42

1.74

0.19

1.76

1.42

1.54

0.22

0.14

3.47

0.06

0.25

0.14

3.23

0.07

0.02

3.62

0.06

0.03

0.02

3.62

0.06

PANSS: Positive and Negative Syndrome Scale; SE: standard error.
aPoor adherence: adherence distribution to antipsychotics, (>0 to <80%); good adherence: adherence distribution to antipsychotics, ≥80%.
Independent variables tested as p≤0.15 in univariate analysis were screened automatically by using stepwise methods and analyzed in the multivariate Cox regression model.
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Table 4. Multivariate Cox regression analysis of time to first relapse with usage of paliperidone palmitate one-month formulation (PP1M)/all longacting injectable (LAI) antipsychotics.
PP1M

Patients with poor adherence to antipsychotics (adherence distribution of all antipsychotics
(>0, <80%), n=39
Usage of PP1M/all LAI antipsychoticsa
No use versus continued use
Interrupted use versus continued use
Total PANSS scores at baseline in the acute phase
Patients with good adherence to antipsychotics
(adherence distribution of all antipsychotics (≥80%),
n=288
Usage of PP1M/all LAI antipsychoticsb
No use versus continued use
Interrupted use versus continued use
Total PANSS scores at baseline in the acute phase

All LAI antipsychotics

Hazard ratio

95% CI

p-Value

Hazard ratio

13.13
11.04
1.06

1.33–129.96
1.03–118.60
1.01–1.11

0.0277
0.0474
0.0285

0.47–2.97
0.45–5.65
0.98–1.05

0.7308
0.4709
0.3516

1.18
1.59
1.01

95% CI

p-Value

13.37
11.08
1.06

1.37–130.14
1.04–118.18
1.01–1.11

0.0255
0.0465
0.0299

1.43
1.74
1.01

0.57–3.60
0.49–6.18
0.98–1.05

0.4485
0.3900
0.3561

CI: confidence interval; PANSS: Positive and Negative Syndrome Scale.
aPP1M: no use, n=20; continued use, n=13; interrupted use, n=6; All LAI antipsychotics: no use, 19; continued use, n=14; interrupted use, n=6.
bPP1M: no use, n=185; continued use, n=74; interrupted use, n=29; All LAI antipsychotics: no use, 174; continued use, n=84; interrupted use, n=30.

in schizophrenia. The Kaplan-Meier plots corroborated this
observation (Figure 2(g) and (h)).

Safety
Safety was evaluated in 362 patients who continued the study for
≥30 days after the last PP1M injection of acute phase. During the
one-year observational period, 50 (13.8%) patients experienced
TEAEs. The most commonly reported TEAEs (in ≥1% patients)
were schizophrenia (2.8%), extrapyramidal disorder (1.9%),
weight gain (1.7%), nasopharyngitis, abnormal liver function
(1.4% each), and upper respiratory tract infection (1.1%). Only
one patient experienced schizophrenia that led to treatment discontinuation, and serious TEAEs were reported in 12 (3.3%)
patients. One death (cause unknown) was reported during the
observational follow-up phase (Table 5).

Discussion
Prevention of symptomatic relapses during maintenance treatment in schizophrenia is an important clinical outcome with several short- and long-term benefits. In the current study in Chinese
patients, a large number of patients who were maintained on
antipsychotic therapy after the 13-week acute PP1M treatment
remained relapse-free during the one-year follow-up period. This
finding was consistent with the low relapse rates observed in the
global PP1M study (Hough et al., 2010). Findings from the exposure analysis were suggestive of variability in the effect of PP1M
in delaying TFR. The efficacy of relapse prevention was largely
dependent on the continuity of PP1M usage and this influence
had a greater clinical significance in patients with suboptimal
antipsychotic adherence.
Among the variables examined in the study, poor antipsychotic adherence and higher numbers of hospitalizations in the

previous year were significant risk factors for relapses in the univariate analysis. This finding is consistent with data from prior
studies identifying suboptimal adherence/nonadherence as one of
the key and modifiable factors influencing symptom exacerbations in patients receiving antipsychotics (Agid et al., 2010;
Ascher-Svanum et al., 2006; Gharabawi et al., 2006; Kaplan
et al., 2013; Nasrallah and Lasser, 2006; Robinson et al., 1999;
Xiao et al., 2015).
Patients with suboptimal antipsychotic adherence and who
discontinued or sporadically used PP1M/all LAI antipsychotics
after the acute PP1M treatment period had a significantly
increased risk of relapse risk when compared with patients who
continued treatment with PP1M during the one-year observational
period. The similarities in HR for no use and interrupted use of
PP1M/all LAI antipsychotics suggest that the benefits of LAI
antipsychotic treatment are undermined by any disruption in treatment continuity. These results suggest that continued LAI antipsychotic use is effective in minimizing the gap between any level of
antipsychotic nonadherence that is greater than 20% and the associated downstream symptomatic relapses. The convenience of
reduced dosing frequency and protracted dosing interval with LAI
antipsychotics offers a distinct advantage over oral antipsychotics
in patients with antipsychotic nonadherence or partial adherence
(Berwaerts et al., 2015; Samtani et al., 2009). In patients with
≥80% antipsychotic adherence (oral/ PP1M and other LAI antipsychotics) the relapses were not influenced by the usage of PP1M
during the one-year follow-up period. The number of patients
with good adherence (nearly 80%) in this study was generally
higher than those commonly observed in clinical practice.
Potential reasons for this observation include an initial selection
bias toward patients with greater illness insight and readiness to
adhere to treatments (as they were part of the 13-week, acute, controlled study phase), reminders to patients for their return to follow-up visits, and patients’ awareness that their adherence was
being measured during the naturalistic follow-up period.
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(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

Figure 2. Kaplan–Meier plots for time to first relapse. (a) Relapse-free survival in patients with good adherence to antipsychotics and on continued
use versus no use of all long-acting injectable (LAI) antipsychotics; (b) relapse-free survival in patients with good adherence to antipsychotics and
on continued use versus interrupted use of all LAIs; (c) relapse-free survival in patients with poor adherence to antipsychotics and on continued use
versus no use of all LAIs; (d) relapse-free survival in patients with poor adherence to antipsychotics and on continued use versus interrupted use of
all LAIs; (e) relapse-free survival in patients with good adherence to antipsychotics and on continued use versus no use of paliperidone palmitate
one-month formulation (PP1M); (f) relapse-free survival in patients with good adherence to antipsychotics and on continued use versus interrupted
use of PP1M; (g) relapse-free survival in patients with poor adherence to antipsychotics and on continued use vs interrupted use of PP1M; (h)
relapse-free survival in patients with poor adherence to antipsychotics and on continued use versus interrupted use of PP1M.
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Table 5. Summary of treatment-emergent adverse events (TEAEs)
reported for patients who continued the study for ≥30 days during the
one-year observational follow-up phase (safety analysis set).
Total
(n=362)
Patients with TEAEs, n (%)
TEAE leading to treatment discontinuation, n (%)
Patients with ≥1 serious TEAE, n (%)
TEAEs leading to death, n (%)
TEAEs reported in ≥1% patients, n (%)
Schizophrenia
Extrapyramidal disorder
Weight gain
Nasopharyngitis
Abnormal liver function
Upper respiratory tract infection

50 (13.8)
1 (0.3)
12 (3.3)
1 (0.3)
10 (2.8)
7 (1.9)
6 (1.7)
5 (1.4)
5 (1.4)
4 (1.1)

Overall, the TEAEs reported during the one-year naturalistic
treatment period were consistent with the known safety and tolerability profile of PP1M (Gopal et al., 2011; Hough et al., 2010;
Pandina et al., 2010; Pandina et al., 2011). No new safety concerns pertaining to use of LAI antipsychotics emerged. Previous
studies of PP1M conducted in patients from the Asia-Pacific
region have reported improvement in patients’ psychotic symptoms and functioning as well as reduction in schizophrenia-related
hospitalizations during long-term PP1M maintenance treatment
(Li et al., 2011; Li et al., 2016; Takahashi et al., 2013; Zhang et al.,
2015). These positive findings extend not only to patients with
chronic, multi-episode illness, but also to first-episode and early
phase patients with illness onset within the past five years (Si
et al., 2015a; Zhang et al., 2015). In the primary 13-week clinical
study, patients with suboptimal responses to prior oral antipsychotics responded favorably to PP1M treatment, with 73%
patients achieving the primary efficacy endpoint (≥30% improvement in the PANSS total score) (Si et al., 2015b). Thus, these
results of this study combined with observations from the primary
study and available evidence, lend support to the potential of
uninterrupted LAI antipsychotic treatment over time in maintaining symptom remission and prevention of relapses in schizophrenia (Correll et al., 2016; Robinson et al., 1999).
Although the naturalistic treatment selection and observational setting of the study are more aligned with everyday clinical
practice as compared to randomized controlled and comparative
studies, these results should be interpreted within the context of
certain limitations of the study. First, the open-label design may
have introduced a potential bias affecting patient-related and
physician-related outcomes, and the non-comparative design of
the study may limit the interpretation of these results. Second, the
study was designed to evaluate relapse prevention in patients
with stable schizophrenia (following treatment with PP1M in the
acute phase). Although this enrichment strategy minimizes the
influence of confounding factors, it potentially limits the generalizability of the study results. Nevertheless, the study intended to
evaluate the potential longer-term benefits of PP1M and LAI
antipsychotic treatment in general, and, clinically, treatment is
continued in patients who have demonstrated acute treatment
benefits. The assessment of adherence was based on monitoring
of prescription practice during the one-year follow-up phase and

did not account for potential discrepancies between prescription
and actual use. Lastly, the effect of concomitant medications or
non-pharmacologic interventions was neither controlled nor systematically assessed, precluding the assessment of a potential
influence on the findings.
In summary, >30% of patients continued on LAI antipsychotic therapy (of which >90% continued PP1M) during the oneyear naturalistic treatment period following acute stabilization
with PP1M. Treatment with PP1M also showed acceptable tolerability during long-term disease management. The efficacy of
uninterrupted PP1M and all LAI antipsychotics in delaying TFR
during the follow-up period was more pronounced in patients
with risk factors for relapse. These risk factors included, partial
or poor antipsychotic adherence (during the one-year study
period), a history of hospitalizations in the past year, and greater
illness severity at the acute treatment baseline. Collectively, these
data may assist clinicians in selecting patients who may benefit
the most from maintenance treatment with LAI antipsychotics.
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